Compare Roblox Corp (RBLX) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roblox Corp vs ResMed Inc. — how do they compare? Roblox Corp trades at $48.11 (market cap $32.52B), while ResMed Inc. trades at $230.12 (market cap $31.89B). The key difference: Roblox Corp and ResMed Inc. are close in size by market cap, and ResMed Inc. pays a 1.16% dividend while Roblox Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Roblox Corp for 93 Days and ResMed Inc. for 51 Days on average.
| RBLX | RMD | |
|---|---|---|
Market Cap | $32.52B | $31.89B |
Volume | 14,552,045 | 618,314 |
Sector | Technology | Health |
52-Week High | $138.56 | $277.88 |
52-Week Low | $35.54 | $182.82 |
Typical Hold Time | 93 Days | 51 Days |
Enterprise Value | $31.34B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Roblox (RBLX) trades at $48.74, up 5.02% in the last session, with technical indicators showing bearish momentum despite recent price strength. The company continues to demonstrate strong revenue growth, reaching $4.89 billion in 2025, but remains unprofitable with a net income margin of -17.61%. Recent analyst downgrades from Jefferies highlight concerns about bookings growth, while AI development tools show potential for long-term platform expansion.
The stock faces near-term headwinds from bearish technical signals and valuation concerns, but strong revenue growth and AI innovation provide long-term potential. Key risks include persistent profitability challenges and competitive pressures in the gaming sector, while analyst consensus suggests modest upside to the $50.85 price target.
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
